Characterization of gastrointestinal disorders in patients with parkinsonian syndromes.

Parkinsonism Relat Disord

Department of Gastroenterology, Seoul National University-Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Republic of Korea.

Published: May 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: This study was aimed to investigate gastrointestinal (GI) dysfunction in patients with Parkinson's disease (PD) compared with those in patients with other parkinsonian disorders, and to characterize parkinsonian motor and non-motor correlates for GI dysfunction.

Methods: Consecutive patients with PD, atypical parkinsonism (P-plus) and vascular parkinsonism (VP) were enrolled in this multicenter systematic survey. Data for weight loss, appetite loss, sialorrhea, dysphagia, gastroesophageal reflux disease (GERD) and constipation were simultaneously collected using symptom-specific, structured questionnaires. For the PD group, information for onset age, PD duration, anti-parkinsonian drug dosages, unified PD rating scale, and Hoehn & Yahr stage were collected at the time of the interview.

Results: Enrolled in the study were 329 PD, 82 P-plus, and 62 VP patients. GI symptom frequencies were similar in PD and other parkinsonian groups. Among the PD patients, constipation was the most common symptom, followed by appetite loss, weight loss, dysphagia, sialorrhea, and GERD (64.9%, 45.4%, 35.7%, 19.4%, 15.0%, and 9.6%, respectively). Dysphagia, sialorrhea, and constipation became more frequent with more advanced PD stages. Cognition, sleep and mood disturbances were significantly associated with weight loss, appetite loss, and dysphagia, whereas bradykinesia, axial and postural instability with gait disturbance were associated with dysphagia.

Conclusions: GI disturbance is common in patients with non-PD parkinsonism as well as in those with PD. GI symptoms correlated with distinct parkinsonian motor and nonmotor features in PD. Further studies are warranted to reveal the pathophysiological mechanisms and prognostic features of GI disturbances in parkinsonian disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2015.02.005DOI Listing

Publication Analysis

Top Keywords

weight loss
12
appetite loss
12
patients parkinsonian
8
parkinsonian disorders
8
parkinsonian motor
8
loss appetite
8
loss dysphagia
8
dysphagia sialorrhea
8
patients
7
parkinsonian
6

Similar Publications

Importance: Neonatal intensive care has advanced over recent decades, yet premature birth remains associated with increased neonatal mortality and morbidity.

Objective: To describe health service use, morbidity, and medication needs up to age 5 years in a contemporary cohort of children born preterm.

Design, Setting, And Participants: This population-based cohort study was conducted in British Columbia (BC), Canada, using health service and pharmacy data linked using provincial administrative databases.

View Article and Find Full Text PDF

The ameliorative effect of Lactiplantibacillus plantarum SCS2 on DSS-induced murine colitis.

Arch Microbiol

September 2025

School of Public Health, Chengdu University of Traditional Chinese Medicine, No. 1166, Liutai Avenue, Wenjiang District, Chengdu, 611137, Sichuan Province, China.

The inhibitory effects of Lactiplantibacillus plantarum on inflammatory responses are known, but its action mechanisms in oxidative stress, immunomodulation, and intestinal homeostasis remain of interest. Accordingly, we investigated the protective effects of Lactiplantibacillus plantarum SCS2 (L. plantarum SCS2) against sodium dextran sulfate (DSS)-induced colitis in mice as well as elucidated its impact on inflammation, oxidative stress, and intestinal microbiota.

View Article and Find Full Text PDF

Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.

Osteoporos Int

September 2025

Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.

Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).

View Article and Find Full Text PDF

Vertebrate animals and many small DNA and single-stranded RNA viruses that infect vertebrates have evolved to suppress genomic CpG dinucleotides. All organisms and most viruses additionally suppress UpA dinucleotides in protein-coding RNA. Synonymously recoding viral genomes to introduce CpG or UpA dinucleotides has emerged as an approach for viral attenuation and vaccine development.

View Article and Find Full Text PDF